Preference for gamma-hydroxybutyrate (GHB) in current users

Gamma-hydroxybutyrate (GHB) is a drug with significant abuse potential. The present study aimed to assess the relative value of escalating doses of GHB to current GHB users via the Multiple Choice Procedure (MCP), and to validate that the dose rated highest with the MCP would be self-administered at a greater rate than placebo. Participants were 5 current GHB users who were not currently trying to stop using GHB. To examine the value of escalating doses of GHB, the following doses of GHB were used: 0 (placebo), 12.5, 25, 37.5, and 50 mg/kg. Participants typically assigned higher doses of GHB had higher crossover points on the MCP. During choice sessions, participants made repeated choices between administering GHB, placebo or nothing. All participants selected GHB exclusively (5 out of 5 instances) except for one participant who selected GHB on 4 out of 5 instances, thus 96% (i.e., 24/25) of choices were for active GHB. Based on these data, GHB appears likely to function as a dose-dependent reinforcer for humans based on our sample.     

Agoraphobia: a critical review of methodology in behavioural treatment research

This review focuses on the methodological status of the literature on behavioural treatment of agoraphobia. Thirty-three studies published between 1963 and 1979 are analysed using a methodological rating scale by which each study is assessed on the extent to which it meets eight basic criteria for outcome research. It is concluded that methodological weaknesses in these reports make questionable any general conclusions about the value of the behavioural treatment of agoraphobia, and recommendations are made concerning possible changes in the future direction of research in this area.     

Maintenence of improvement in agoraphobic patients treated by behavioural methods—a four-year follow-up

Fifty-six agoraphobic patients who had shown clinical improvement when treated by behavioural methods were followed-up between 3.0 and 6.3 yr (mean 4.3 yr) later. Comparison of pre- and post-treatment and follow-up self-assessment data showed that improvement had been maintained on all the variables assessed—main symptom, other phobias, depression, social relationships and disruption at work. Only one patient reported the emergence of new psychological symptoms. However, only 10 (18%) of the sample described themselves as completely symptom-free, although most of the remainder reported that their symptoms caused them only slight distress, and little disruption in their lives.     

Towards a Christian bioethics.

Rather than revealing itself as a single, unified, ecumenical faith, Christianity is sundered with Christians united neither in one communion nor in one baptism. Christian Bioethics seeks to examine the traditional content-full moral commitments which the Christian faiths bring to life, sexuality, suffering, illness and death within the contexts of medicine and health care. Seeking to understand the differences which separate the bioethics of Roman Catholics, Protestants, and the Orthodox, Christian Bioethics explores the manners in which the faiths diverge. The failure of the Enlightenment project to disclose a content-full communality that would bind mankind has left much to be reconsidered by Christians who face new ethical dilemmas in the novel guise of advances in health care technologies.     

Physician-assisted death: doctrinal develoment vs. Christian tradition.

Physician-assisted suicide offers a moral and theological Rorschach test. Foundational commitments regarding morality and theology are disclosed by how the issue is perceived and by what moral problems it is seen to present. One of the cardinal differences disclosed is that between Western and Orthodox Christian approaches to theology in general, and the theology of dying and suicide in particular. Confrontation with the issue of suicide is likely to bring further doctrinal development in many of the Western Christian religions, so as to be able to accept physician-assisted suicide and euthanasia.     

National agenda for children with special health needs. Social policy for the 1990s through the 21st century.

The evolution in medical technology for children with special health care needs has been accompanied by an evolution in concepts of care. Broadened diagnostic categories, comprehensive concern for the whole child, and coordinated services that are family-centered and community-based have become part of the national agenda. During the 1980s this agenda was advanced both by congressional action and by joint activities of the U.S. Public Health Service and the private sector. Much remains to be accomplished. Increased parent participation and activism, an integral part of the future, will require vigilant nurturing and support.